Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237516 · ClinicalTrials.gov registry record
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
A clinical trial of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- 200
- Enrollment target
- 5
- Study locations
NCT07237516: Recruiting study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), sponsored by University of North Carolina, Chapel Hill.
NCT07237516 is a study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD) that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 200 participants, below the 753-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (73% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07237516, a study of Ulcerative Colitis (UC) and Inflammatory Bowel Disease (IBD), is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.
Primary Outcome
The SCCAI is a 6-item that describes the symptoms and disease activity of a patient with UC at the time of assessment. A score of 0-4 is considered a clinical range of remission (but with more refined definitions of clinical remission with SCCAI ≤2 and very mild symptoms with a score \>2 ≤4), 5-7 mild activity, 8-16 moderate activity and \> 16 severe activity. A response will be defined as a decrease of the SCCAI score \< 5 points in patients with a baseline SCCAI ≥5.
Conditions Studied
Study Locations (5)
Iowa
- University of Iowa - Iowa City
Maryland
- Mercy Medical Center - Baltimore
Massachusetts
- Brigham and Women's Hospital - Boston
New York
- New York University - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2028-11-03 |
What NCT07237516 shows while recruiting
NCT07237516 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 753-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (73% lower).
The record links to 4 conditions, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 0 interventions.
NCT07237516 lists 5 locations in 5 states (Iowa, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT07237516 about?
NCT07237516 is a clinical study titled "Zymfentra (Infliximab-dyyb) REal World Cohort STudy". The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb...
What is the current status of trial NCT07237516?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-11-20. Estimated completion is 2028-11-03.
What conditions does trial NCT07237516 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD), Indeterminate Colitis, Crohn's Disease (CD).
Who is sponsoring clinical trial NCT07237516?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07237516 being conducted?
This trial has 5 study locations across Iowa, Maryland, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07237516's enrollment target sits among peer trials
200 6th of 17 higher than 11 of 17 other Ulcerative Colitis (UC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis (UC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
-
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
RECRUITING · Phase 1
-
Evaluation of the SMART IBD App in Pediatric IBD
RECRUITING · NA
-
Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI